The Beech Boys are selling "long 2 weeks"What for ( cause they're asked to ) but really WHY?
The interim data signaled at 12% absolute efficacy at 600 patients ( 650 was settled upon )
The knowledgeable GMP analyst suggests 10% is the downside and values the stock at $1
He also states that 15% would drive a $3 share price.
12% = $1.75 and is the floor
The chosen 176 patients ( 2nd page of Spetember 2015 NR ) yeah, 2nd page! Backs a 20$ expected absolute efficacy. Any suggestion of a sub 20% absolute benefit would have seen the FDA call for additional patients.
These shares must be more valuable than I imagined given the decade long fairy tale told here.
Sqr